Do you want to read an article? Please log in or register.
Comparative Outcomes of Segmentectomy Versus Lobectomy for Solid Dominant Lung Cancer with a Tumor Diameter of 2-3 cm
Lung Cancer
Related content
Lung Cancer
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S
doi: 10.1016/j.lungcan.2025.108840
RECOMMENDED
Further Publications
Does robotic segmentectomy improve long-term outcomes in non-small cell lung cancer?
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Eur J Cardiothorac Surg
Berjaoui N, Fabbri G, Lampridis S, Maraschi A, Harrison-Phipps K, Routledge T, Patel A, Bille A
doi: 10.1093/ejcts/ezag048
RECOMMENDED
Lung Cancer
Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Aiba T, Hara S, Tominaga S, Yamamoto R, Sakashita H, Sakaguchi T, Ando Y, Koshio J, Takigami A, Maemondo M, Sugawara S
doi: 10.1016/j.lungcan.2026.109355
RECOMMENDED
Lung Cancer
Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Lopez I, Aguinagalde B, Ferrer-Bonsoms JA, Sánchez L, Ascanio F, Sesma J, Recuero JL, Fernandez-Monge A, Lizarbe JA, Embun R
doi: 10.3390/jcm14072267
Lung Cancer
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
Clin Lung Cancer
Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G, Hochmair M, Özgüroğlu M, Ji JH, Garassino MC, Poltoratskiy A, Verderame F, Havel L, Bondarenko I, Losonczy G, Conev N, Kummer S, Mann H, Chugh P, Dalvi T, Paz-Ares L
doi: 10.1016/j.cllc.2025.08.001
RECOMMENDED
Lung Cancer
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Vakkalagadda CV, Bucheit L, Clemens K, Saha J, Zhang N, Patel JD
doi: 10.1016/j.cllc.2025.07.007
Lung Cancer
10-Year Long-Term Outcomes of Robotic-Assisted Segmentectomy for Early-Stage Non-Small-Cell Lung Cancer
J Clin Med
Casiraghi M, Orlandi R, Mazzella A, Girelli L, Caffarena G, Chiari M, Bertolaccini L, Lo Iacono G, Diotti C, Bardoni C, Maisonneuve P, Spaggiari L
doi: 10.3390/jcm14165608
Lung Cancer
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
Lancet Respir Med
Wang L, Hao X, Hao Y, Hu Y, Chen C, Chen B, Huang Y, Zang A, Wang Y, Chen Z, Zhuang W, Shi J, Ren X, Nie L, Yu G, Luo F, Mao Y, Wang X, Li B, Bai Y, Shi J, Ni H, Yu H, Li J, Wang Q, Zhu J, Shi Y, ASTRUM-002 Study Group
doi: 10.1016/S2213-2600(25)00263-2
Lung Cancer
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lancet Respir Med
Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group
doi: 10.1016/S2213-2600(25)00121-3